CA2667816A1 - Inhibiteurs de proteases de type cathepsines - Google Patents

Inhibiteurs de proteases de type cathepsines Download PDF

Info

Publication number
CA2667816A1
CA2667816A1 CA002667816A CA2667816A CA2667816A1 CA 2667816 A1 CA2667816 A1 CA 2667816A1 CA 002667816 A CA002667816 A CA 002667816A CA 2667816 A CA2667816 A CA 2667816A CA 2667816 A1 CA2667816 A1 CA 2667816A1
Authority
CA
Canada
Prior art keywords
compound
optionally substituted
cathepsin
compounds
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002667816A
Other languages
English (en)
Inventor
Robert Epple
Ross Russo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
Irm Llc
Robert Epple
Ross Russo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc, Robert Epple, Ross Russo filed Critical Irm Llc
Publication of CA2667816A1 publication Critical patent/CA2667816A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002667816A 2006-10-23 2007-10-17 Inhibiteurs de proteases de type cathepsines Abandoned CA2667816A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86250006P 2006-10-23 2006-10-23
US60/862,500 2006-10-23
PCT/US2007/081635 WO2008051763A1 (fr) 2006-10-23 2007-10-17 Inhibiteurs de protéases de type cathepsines

Publications (1)

Publication Number Publication Date
CA2667816A1 true CA2667816A1 (fr) 2008-05-02

Family

ID=39091868

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002667816A Abandoned CA2667816A1 (fr) 2006-10-23 2007-10-17 Inhibiteurs de proteases de type cathepsines

Country Status (9)

Country Link
EP (1) EP2078027A1 (fr)
JP (1) JP2010507681A (fr)
KR (1) KR20090064463A (fr)
CN (1) CN101589047A (fr)
AU (1) AU2007309195A1 (fr)
BR (1) BRPI0717348A2 (fr)
CA (1) CA2667816A1 (fr)
MX (1) MX2009004290A (fr)
WO (1) WO2008051763A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744987C (fr) 2008-12-02 2018-01-16 Chiralgen, Ltd. Procede pour la synthese d'acides nucleiques modifies par des atomes de phosphore
EP2451461A4 (fr) 2009-07-06 2013-05-29 Ontorii Inc Nouveaux précurseurs d'acide nucléique et leurs méthodes d'utilisation
EP2620428B1 (fr) * 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Groupe auxiliaire asymétrique
ES2626488T3 (es) 2011-07-19 2017-07-25 Wave Life Sciences Pte. Ltd. Procedimientos para la síntesis de ácidos nucleicos funcionalizados
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
KR102213609B1 (ko) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 키랄 제어
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP3095461A4 (fr) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Adjuvant d'acide nucléique chiral possédant une activité d'induction d'immunité, et activateur d'induction d'immunité
MY193116A (en) 2014-01-16 2022-09-26 Wave Life Sciences Ltd Chiral design
WO2016014522A1 (fr) 2014-07-21 2016-01-28 Brandeis University Inhibiteurs de protéases de désubiquitination

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7297714B2 (en) * 2003-10-21 2007-11-20 Irm Llc Inhibitors of cathepsin S

Also Published As

Publication number Publication date
WO2008051763A1 (fr) 2008-05-02
BRPI0717348A2 (pt) 2013-10-15
KR20090064463A (ko) 2009-06-18
JP2010507681A (ja) 2010-03-11
EP2078027A1 (fr) 2009-07-15
AU2007309195A1 (en) 2008-05-02
CN101589047A (zh) 2009-11-25
MX2009004290A (es) 2009-07-27

Similar Documents

Publication Publication Date Title
CA2667816A1 (fr) Inhibiteurs de proteases de type cathepsines
US9453048B2 (en) IAP antagonists
TW502020B (en) Arylsulfonyl hydroxamic acid derivatives
OA11594A (en) Hydroxy pipecolate hydroxamic acid derivatives as MMP inhibitors.
AU2004204692A1 (en) Macrocyclic beta-secretase inhibitors for treatment of Alzheimer's disease
US8921394B2 (en) Prolylcarboxypeptidase inhibitors
JP2002536373A (ja) スルファメトヒドロキサム酸メタロプロテアーゼ阻害剤
KR20040089705A (ko) 칼리크레인의 선택적 디펩타이드 억제제
JP2015533173A (ja) タンパク質脱アセチル化酵素阻害剤としてのピリミジンヒドロキシアミド化合物およびその使用方法
DE10322191B4 (de) N-sulfonylierte Aminosäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US9000182B2 (en) 2H-imidazol-4-amine compounds and their use as BACE inhibitors
JP7130873B2 (ja) バニン阻害剤としてのヘテロ芳香族化合物
US5571921A (en) Substituted (2-oxo-1-benzimidazolinyl)-peperidines, process for their preparation, and use as anti-retroviral agents
WO2011156220A1 (fr) Nouveaux inhibiteurs de prolylcarboxypeptidase
KR20170002407A (ko) C형 간염 바이러스의 강력하고 선택적인 저해제
US20100113549A1 (en) Pyrrolidine compounds
CZ2002498A3 (cs) Deriváty kyseliny hydroxamové a N-formylhydroxylaminu a farmaceutický prostředek
AU2014214325A1 (en) Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis
EP2132174B1 (fr) Amides d'aminoacides secondaires de phénylsulfonylamide méta-substitué, leur production et leur utilisation comme inhibiteurs de la matriptase
WO1999048911A1 (fr) Monobactams inhibiteurs d'enzymes
WO2009038411A2 (fr) Composés inhibiteurs de la béta-sécrétase contenant un fragment d'oxo-dihydro-pyrazole
JPH06329678A (ja) 多環式化合物及びその製造方法
EP1140897A1 (fr) Inhibiteurs de proteases
CZ200392A3 (cs) Aminoisochinolinové deriváty
Cao et al. Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead